leisure time -WSS

leisure time

author：hotspot 2025-10-02 01:08:04 - browse：8455

Mifepristone (Mifeprex) and Misoprostol — A federal appeals court on Wednesday ruled to restrict access to the abortion pill mifepristone but not remove it from the market entirely. ROBYN BECK/AFP via Getty Images

A federal appeals court on Wednesday ruled to restrict access to the abortion pill mifepristone but not remove it from the market entirely, partially upholding a lower court’s decision.

The decision from the three-judge panel of the 5th U.S. Circuit Court of Appeals would effectively block mail-order prescriptions of the pill. However, access will remain unchanged for now, as the Supreme Court issued an emergency order this spring to preserve the status quo while the case goes through the appeals process.

The case is all but assured to head to the highest court, which last year overturned Roe v. Wade. Since the ruling, 14 states have implemented abortion bans and another 11 have imposed limits, some up to six weeks of pregnancy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

WSS

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Ionis drug prevents swelling attacks due to hereditary angioedema

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO: AstraZeneca says CAR

AMAs digital advisors table RPM coding reform proposal, again

Letters to First Opinion on caregivers, digital health, and more

entertainment

leisure time

focus

Continuity nursing helped my family in our darkest PICU moments

NIH documents show early flaws of $1.6 billion long Covid program

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Cancer drug shortages should be causing more outrage

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Medical records are filled with copy

With trial win, GSK could get blood cancer drug back on market

New air purifier tech could be key to improving indoor air quality

Long Covid research funding gets a major boost from NIH

entertainment

Congress must protect the remaining independent doctors

Why don't Americans have at

Ultragenyx gene therapy for rare liver ailment succeeds in late

Ultragenyx gene therapy for rare liver ailment succeeds in late

ASCO: AstraZeneca says CAR

Kaiser's Risant Health gobbled up Geisinger. Who is next?

entertainment

focus

knowledge

explore